Search in:

Expert Opinion on Pharmacotherapy Volume 11, 2010 - Issue 8

Submit an article Journal homepage

Free access

2,383

Views

CrossRef citations to date

Altmetric

Drug Evaluations

Pemetrexed in advanced non-small-cell lung cancer

Alexander D Fuld Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA +1 603 650 6432; +1 603 650 2334; [email protected]

Konstantin H Dragnev Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA +1 603 650 6432; +1 603 650 2334; [email protected]

James R Rigas Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA +1 603 650 6432; +1 603 650 2334; [email protected]

Pages 1387-1402 | Published online: 06 May 2010

Cite this article
https://doi.org/10.1517/14656566.2010.482560

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions
View PDF PDF

Figures & data

Box 1. Drug summary.

Display Table

Figure 1. Pemetrexed mechanism of action.

Table 1. Notable trials of pemetrexed in second-line treatment of advanced NSCLC.

Download CSV Display Table

Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6:363-73

PubMed Web of Science ®Google Scholar

Hanna N, Shepherd FA, Fossella FV, Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97

PubMed Web of Science ®Google Scholar

Cullen MH, Zatloukal P, Sorenson S, A randomized Phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 2008;19:939-45

PubMed Web of Science ®Google Scholar

Smit EF, Mattson K, von Pawel J, ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a Phase II study. Ann Oncol 2003;14:455-60

PubMed Web of Science ®Google Scholar

Ohe Y, Ichinose Y, Nakagawa K, Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4206-12

PubMed Web of Science ®Google Scholar

Smit EF, Burgers SA, Biesma B, Randomized Phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-45

PubMed Web of Science ®Google Scholar

Scagliotti GV, Parikh P, von Pawel J, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51

PubMed Web of Science ®Google Scholar

Gronberg BH, Bremnes RM, Flotten O, Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-24

PubMed Web of Science ®Google Scholar

Schiller JH, Harrington D, Belani CP, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8

PubMed Web of Science ®Google Scholar

Rusthoven JJ, Eisenhauer E, Butts C, Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a Phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:1194-9

PubMed Web of Science ®Google Scholar

Manegold C, Gatzemeier U, von Pawel J, Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter Phase II trial. Ann Oncol 2000;11:435-40

PubMed Web of Science ®Google Scholar

Shepherd FA, Dancey J, Arnold A, Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001;92:595-600

PubMed Web of Science ®Google Scholar

Clarke SJ, Abratt R, Goedhals L, Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002;13:737-41

PubMed Web of Science ®Google Scholar

Zinner RG, Fossella FV, Gladish GW, Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005;104:2449-56

PubMed Web of Science ®Google Scholar

Scagliotti GV, Kortsik C, Dark GG, Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, Phase II trial. Clin Cancer Res 2005;11:690-6

PubMed Web of Science ®Google Scholar

Stathopoulos GP, Dimitroulis J, Toubis M, Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a Phase I-II trial. Lung Cancer 2007;57:66-71

PubMedGoogle Scholar

Clarke SJ, Boyer MJ, Millward M, A Phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 2005;49:401-12

PubMed Web of Science ®Google Scholar

Monnerat C, Le Chevalier T, Kelly K, Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2004;10:5439-46

PubMed Web of Science ®Google Scholar

Ma CX, Nair S, Thomas S, Randomized Phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5929-37

PubMed Web of Science ®Google Scholar

Treat J, Bonomi P, McCleod M, Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a Phase II trial. Lung Cancer 2006;53:77-83

PubMedGoogle Scholar

West HL, Wakelee HA, Perry MC, Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a Phase II clinical trial. Ann Oncol 2009;20:850-6

PubMedGoogle Scholar

Gridelli C, Kaukel E, Gregorc V, Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, Phase II trial. J Thorac Oncol 2007;2:221-9

PubMed Web of Science ®Google Scholar

Dudek AZ, Larson T, McCleod MJ, Phase I/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol 2008;3:394-9

Google Scholar

Blakely LJ, Schwartzberg L, Keaton M, A Phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2009;66:97-102

Google Scholar

Ciuleanu T, Brodowicz T, Zielinski C, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase III study. Lancet 2009;374:1432-40

PubMed Web of Science ®Google Scholar

Kubota K, Niho S, Enatsu S, Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase ii study. J Thorac Oncol 2009;4(12):1530-6

Google Scholar

A Phase II trial of carboplatin, bevacizumab and pemetrexed in advanced non-small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00614822 [Last accessed January 2010]

Google Scholar

Pemetrexed plus bevacizumab in pretreated, advanced or metastatic non small cell lung cancer (NSCLC). Available from: http://clinicaltrials.gov/ct2/show/NCT00741221 [Last accessed January 2010]

Google Scholar

Patel JD, Bonomi P, Socinski MA, Treatment rationale and study design for the pointbreak study: a randomized, open-label Phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009;10:252-6

PubMed Web of Science ®Google Scholar

A study of tarceva (erlotinib) and standard of care chemotherapy in patients with advanced, recurrent, or metastatic non-small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00556322 [Last accessed November 2009]

Google Scholar

Trial of pemetrexed versus erlotinib in pretreated patients with non small cell lung cancer (NSCLC). Available from: http://clinicaltrials.gov/ct2/show/NCT00440414 [Last accessed November 2009]

Google Scholar

A Phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment in patients with nonsquamous NSCLC. Available from: http://clinicaltrials.gov/ct2/show/NCT00447057 [Last accessed January 2010]

Google Scholar

A study of induction and maintenance treatment of advanced non-squamous non small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00789373 [Last accessed November 2009]

Google Scholar

Study of patients with advanced non-small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00948675 [Last accessed January 2010]

Google Scholar

Trial of poor performance status patients (ToPPS). Available from: http://clinicaltrials.gov/ct2/show/NCT00892710 [Last accessed March 2010]

Google Scholar

Pemetrexed, carboplatin, and bevacizumab as first-line therapy in treating older patients with stage IIIB or stage IV non-small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00798603 [Last accessed March 2010]

Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Pemetrexed in advanced non-small-cell lung cancer

Box 1. Drug summary.

Table 1. Notable trials of pemetrexed in second-line treatment of advanced NSCLC.

Table 2. Phase III trials of pemetrexed in the first-line treatment of NSCLC.

Table 3. Notable Phase II trials of pemetrexed in the first line.

Table 4. Results from analyses of histology in selected trials of pemetrexed.

Table 5. Selected ongoing trials involving pemetrexed in advanced NSCLC.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pemetrexed in advanced non-small-cell lung cancer

Figures & data

Box 1. Drug summary.

Table 1. Notable trials of pemetrexed in second-line treatment of advanced NSCLC.

Table 2. Phase III trials of pemetrexed in the first-line treatment of NSCLC.

Table 3. Notable Phase II trials of pemetrexed in the first line.

Table 4. Results from analyses of histology in selected trials of pemetrexed.

Table 5. Selected ongoing trials involving pemetrexed in advanced NSCLC.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date